The latest price target for Progyny (NASDAQ:PGNY) was reported by Barclays on March 20, 2026. The analyst firm set a price target for $23.00 expecting PGNY to fall to within 12 months (a possible -2.29% downside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Progyny (NASDAQ:PGNY) was provided by Barclays, and Progyny maintained their overweight rating.

The last upgrade for Progyny Inc happened on January 20, 2026 when Citizens raised their price target to $30. Citizens previously had a market perform for Progyny Inc.

The last downgrade for Progyny Inc happened on December 2, 2024 when JP Morgan changed their price target from $22 to $17 for Progyny Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Progyny, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Progyny was filed on March 20, 2026 so you should expect the next rating to be made available sometime around March 20, 2027.

While ratings are subjective and will change, the latest Progyny (PGNY) rating was a maintained with a price target of $29.00 to $23.00. The current price Progyny (PGNY) is trading at is $23.54, which is out of the analyst’s predicted range.